Recombinant Anti-CD16 x Anti-CD30 Bispecific Antibody (Tandem scFv-Fc) is designed to be expressed as a homodimer, which has 2+2 antigen-binding valency. This format consists of one Fc region and two tandem scFv fragments, in which the anti-CD16/CD30 tandem scFv is fused to the Fc domain. The engineered fragment format is used to extend the half-life. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.
Constant Domain-extended Bispecific Fragments
FuncS; Promising therapeutic agent
Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL)
FCGR3A; Fc fragment of IgG, low affinity IIIa, receptor (CD16a); CD16; FCG3; CD16A; FCGR3; IGFR3; IMD20; FCR-10; FCRIII; FCGRIII; FCRIIIA; low affinity immunoglobulin gamma Fc region receptor III-A; FcγRIII; FcgammaRIIIA; CD16a antigen; fc-gamma RIII; Fc-gamma RIIIa; Fc-gamma RIII-alpha; igG Fc receptor III-2; Fc gamma receptor III-A; Fc-gamma receptor IIIb (CD16); neutrophil-specific antigen NA; Fc-gamma receptor III-2 (CD 16); immunoglobulin G Fc receptor III; Fc fragment of IgG, low affinity III, receptor for (CD16)
TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30
Our services and products are only for lab research, not for any diagnostic or therapeutic use.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email